in the JAVELIN Merkel 200 trial, the anti-PD-L1 agent avelumab was assessed in MCC in patients with ≥ 1 line of chemotherapy or no previous systemic treatment. This evidence concerns the gene CD274 and Merkel cell skin cancer.